

REMARKS

Claims 1-19 are pending. A minor correction has been made to Claim 14. No new matter has been added. A new certified English translation of the foreign priority document is submitted herewith. Favorable reconsideration is now respectfully requested.

The Applicants thank Examiner Patterson for the courteous and helpful discussion of November 25, 2003. The Applicants were encouraged to file a certified English translation of the priority document and translator's declaration identifying the translated document. Such is attached to this response. To address the rejections over Tokuyama et al., U.S. Patent No. 5,525,501 and EP 0 474 965, it was suggested that Applicants further distinguish the differences between the racemase of the *Amycolatopsis orientalis*, subspecies *lurida*, and that of the TS-1 strain of the prior art. The Applicants herewith attach Verseck et al. (abstract), which elaborates on structural differences between these types of *Amycolatopsis*. Accordingly, favorable consideration is now respectfully requested.

Rejection—35 U.S.C. §102(a) or 102(a)/103(a)

Claims 1-19 were rejected under 35 U.S.C. §102(a) over Verseck et al., or under 35 U.S.C. §102(a), or in the alternative under 35 U.S.C. §103(a) over Drauz. A certified English translation of the foreign priority document and translator's declaration is submitted herewith. Support for N-acetyl-amino acid racemase (AAR) from *Amycolatopsis orientalis*, subspecies *lurida*, and for a process using such an AAR is found *inter alia* in Claims 1-3 of this document. These rejections are respectfully traversed on the ground that Verseck et al and Drauz are not prior art against the present application.

Rejection—35 U.S.C. §102(b)

Claims 1-2, 4-9, 11-15, and 17-19 were rejected under 35 U.S.C. §102(b), or in the alternative under 35 U.S.C. §103(a), over Tokuyama et al. (B, U.S. Patent 5,525,501) or (AC, EP 0 474 965).

Claim 1 is directed to a method involving an N-acetyl amino acid racemase (AAR) from *Amycolatopsis orientalis* subspecies *lurida*.

The rejection is concerned that racemase from *Amycolatopsis orientalis* subspecies *lurida* is not distinguishable from a racemase from *Amycolatopsis* sp. TS-1-60, which is disclosed by Tokuyama et al.

The attached document shows that racemases from these two organisms are different. Verseck et al. (abstract, 2001, attached) indicates that the coding gene from N-acetyl amino acid racemase from *Amycolatopsis orientalis* subspecies *lurida* had identities to the *aar* gene of strain TS-1-60 of 86% at the DNA level and 90% at the level of amino acids. Moreover, comparison of SEQ ID NO: 2 of the present application, which shows the amino acid sequence of an AAR from *Amycolatopsis orientalis* subspecies *lurida*, and SEQ ID NO: 2 of the '501 Patent and Fig. 1 of the EP '965 Patent, shows that these organisms encode AARs with different structures. Accordingly, the Applicants submit that based on the above sequence data that one of skill in the art would recognize that the *aar* genes and AAR proteins from these two types of *Amycolatopsis* are significantly divergent and would not encompass the same sequences. Accordingly, the Applicants respectfully request that this rejection now be withdrawn.

Serial No.: 09/973,712

Reply to Office Action of November 17, 2003

CONCLUSION

In view of the above remarks the Applicants respectfully submit that this application is now in condition for allowance. Early notification to that effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

A handwritten signature in black ink, appearing to read "Norman F. Oblon", written in a cursive style.

Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Thomas Cunningham, Ph.D.  
Registration No. 45,394

Customer Number

**22850**

Fax #: (703)413-2220  
NFO/TMC/kr

**Use of acetylamino acid racemase from *Amycolatopsis orientalis* for racemisation of carbamoylamino acids**

The present invention relates to the use of an N-acetyl-amino acid racemase (AAR) in a process for the racemisation  
5 of N-carbamoylamino acids.


Optically pure amino acids are important starting materials for chemical synthesis and for parenteral nutrition. Many possibilities of preparing optically pure amino acids are known to the skilled person. Enzymatic processes, i.a. are  
10 suitable in this respect since, on the one hand, they operate catalytically and on the other hand permit the preparation of the amino acids with very high enantiomer enrichment.

A known enzymatic process starts from racemic hydantoins  
15 which are transformed to N-carbamoyl-protected amino acids by means of hydantoinases. These are then converted by carbamoylases to the amino acids.

The separation of the racemates occurring in this reaction sequence takes place preferably on the basis of the N-carbamoyl-protected amino acids because both L and D-selective carbamoylases are available (Park et al., Nat  
20 Biotechnol. Prog. 2000, 16, 564-570; May et al., Nat Biotechnol. 2000, 18, 317-20; Pietzsch et al., J. Chromatogr. B Biomed. Sci. Appl. 2000, 737, 179-86; Chao et  
25 al., Biotechnol. Prog. 1999, 15, 603-7; Wilms et al., J. Biotechnol. 1999, 68, 101-13; Batisse et al., Appl. Environ. Microbiol. 1997, 63, 763-6; Buson et al., FEMS Microbiol. Lett. 1996, 145, 55-62).

In order to guarantee complete conversion of the hydantoins  
30 used to optically pure amino acids, the necessary racemisation has taken place hitherto on the basis of hydantoins by chemical or enzymatic means (EP 745678; EP 542098; scheme 1).

Scheme 1:



N-acetyl amino acid racemases (AARs) from *Streptomyces*  
 5 *atratus* Y-53 (Tokuyama et al., Appl. Microbiol. Biotechnol.  
 1994, 40, 835-840) and *Amycolatopsis* sp. TS-1-60 (Tokuyama  
 et al., Appl. Microbiol. Biotechnol. 1995a, 42, 853-859)  
 and *Amycolatopsis orientalis* sp. *lurida* (DE19935268) are  
 known. TS-1-60, however, is found to have a very low  
 10 activity in the case of N-carbamoyl-protected amino acids.  
 Moreover, this enzyme has the disadvantage of a very high  
 metal ion dependence, which appears to be a drawback for  
 the use of this enzyme in an industrial-scale process.


The object of the present invention was, therefore, to show  
 15 the use of an N-acetyl amino acid racemase for the improved  
 racemisation of N-carbamoyl amino acids compared with the  
 prior art. The intention was that this racemase might be  
 used advantageously on an industrial scale in a process for  
 the preparation of optically pure amino acid starting from  
 20 racemic hydantoins.

The object is achieved by the use of the AAR according to  
 claim 1. Claims 2 and 3 relate to preferred embodiments of  
 the racemisation process according to the invention.

Due to the fact that an N-acetyl amino acid racemase (AAR) from *Amycolatopsis orientalis* subspecies *lurida* (seq. 2) is used in a process for the racemisation of N-carbamoyl amino acids, and in view of the surprisingly high activity of the AAR used according to the invention compared with TS-1-60 in terms of the racemisation of N-carbamoyl amino acids, it is possible to achieve an equilibrium of enantiomers of N-carbamoyl-protected amino acids in an improved process.

This is particularly advantageous in that it is thus possible to establish a further enzymatic step in a process for the preparation of optically pure amino acids which is based on hydantoins (scheme 2).

Scheme 2:



In contrast to the enzymatic processes known from the literature and which proceed by way of enzymatic or optionally stressing chemical racemisation of hydantoins (scheme 1), a further advantageous possibility of generating optically pure amino acids from racemic hydantoins has thus been created.

The variant of AAR from *Amycolatopsis o. sp. lurida* prepared by recombinant technology according to DE19935268 is preferably used for the racemisation process. It is

known from DE19935268 that this exhibits relatively little heavy metal ion dependence (particularly with regard to cobalt ions) and has low amino acid inhibition. The generation thereof as a recombinant enzyme is also  
5 explained therein.

The process according to the invention, as has been mentioned, is used advantageously in an overall process for the preparation of enantiomerically enriched amino acids or derivatives thereof starting from hydantoins or N-  
10 carbamoylamino acids. In the case of hydantoins, it is preferable to proceed in such a manner that racemic hydantoins are cleaved by hydantoinases into the corresponding racemic N-carbamoylamino acids and these are then converted by L- or D-specific carbamoylases into the  
15 optically active L- or D-amino acids. To ensure that no enrichment of the unconverted enantiomer of an N-carbamoylamino acid takes place in the reaction mixture, the enantiomers of the N-carbamoylamino acids are brought into equilibrium by the addition of the AAR according to  
20 the invention and it is thus likewise possible to convert the racemic hydantoin wholly to optically pure amino acids.

This process takes place preferably in an enzyme-membrane reactor (DE 199 10 691.6).

The enzymes mentioned may be used together or successively  
25 in the free form as homogeneously purified compounds or as enzymes prepared by recombinant technology. Moreover, the enzymes may also be used as a constituent of a guest organism (whole-cell catalyst as in US09/407062) or in conjunction with the digested cell mass of the host  
30 organism. It is also possible to use the enzymes in the immobilised form (Bhavender P. Sharma, Lorraine F. Bailey and Ralph A. Messing, "Immobilisierte Biomaterialien - Techniken und Anwendungen", Angew. Chem. 1982, 94, 836-852). Immobilisation takes place advantageously by freeze-

drying (Dordick et al. J. Am. Chem. Soc. 194, 116, 5009-5010; Okahata et al. Tetrahedron Lett. 1997, 38, 1971-1974; Adlercreutz et al. Biocatalysis 1992, 6, 291-305). Freeze-drying in the presence of surfactant substances such as  
5 Aerosol OT or polyvinylpyrrolidone or polyethylene glycol (PEG) or Brij 52 (diethylene glycol monocetyl ether) (Goto et al. Biotechnol. Techniques 1997, 11, 375-378) is more particularly preferred.

The microorganism *Amycolatopsis orientalis* subsp. *lurida* is  
10 deposited with the German Collection for Microorganisms under number DSM43134.

The term AAR within the context of the invention means both the native enzyme and the enzyme prepared by recombinant technology.

15 The term enantiomerically enriched denotes the presence of one enantiomer in the mixture with the other in a proportion of >50%.

The term amino acid within the context of the invention means a natural or non-naturally occurring  $\alpha$ -amino acid,  
20 i.e., the radical situated on the  $\alpha$ -C-atom of the  $\alpha$ -amino acid may be derived from a natural amino acid as described in Beyer-Walter, Lehrbuch der organischen Chemie, S. Hirzel Verlag Stuttgart, 22nd edition, 1991, p.822f. or also from corresponding  $\alpha$ -radicals of non-naturally occurring amino  
25 acids which are listed, e.g. in DE19903268.8.



## SEQUENCE PROTOCOL

&lt;110&gt; Degussa-Hüls AG

5 <120> Use of an acetylamino acid racemase for the  
racemisation of carbamoylamino acids

&lt;130&gt; 000337 AM

10 &lt;140&gt;

&lt;141&gt;

&lt;160&gt; 2

15 &lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1107

&lt;212&gt; DNA

20 &lt;213&gt; Amycolatopsis orientalis

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1107)

25

&lt;400&gt; 1

gtg	aaa	ctc	agc	ggg	gtg	gaa	ctg	cgc	cgg	gtc	cgg	atg	ccg	ctc	gtg	48
Val	Lys	Leu	Ser	Gly	Val	Glu	Leu	Arg	Arg	Val	Arg	Met	Pro	Leu	Val	
1				5					10					15		

30

gcc	ccg	ttc	cgg	acg	tcg	ttc	ggg	acg	cag	tcc	gag	cgg	gaa	ttg	ctg	96
Ala	Pro	Phe	Arg	Thr	Ser	Phe	Gly	Thr	Gln	Ser	Glu	Arg	Glu	Leu	Leu	
			20					25					30			

35

ctg	gtc	cgc	gcg	gtg	acc	ccg	gcg	ggc	gag	ggc	tgg	ggc	gaa	tgt	gtc	144
Leu	Val	Arg	Ala	Val	Thr	Pro	Ala	Gly	Glu	Gly	Trp	Gly	Glu	Cys	Val	
		35					40					45				

40

gcg	atg	gag	gcg	ccg	ctc	tac	tcg	tcg	gag	tac	aac	gac	gcc	gcc	gag	192
Ala	Met	Glu	Ala	Pro	Leu	Tyr	Ser	Ser	Glu	Tyr	Asn	Asp	Ala	Ala	Glu	
	50					55					60					

45

cac	gtg	ctg	cgg	aac	cat	ctg	atc	ccc	gca	ctg	ctg	gcg	gcc	gag	gac	240
His	Val	Leu	Arg	Asn	His	Leu	Ile	Pro	Ala	Leu	Leu	Ala	Ala	Glu	Asp	
	65				70				75					80		

50

gtg	acc	gcg	cac	aag	gtg	acg	ccg	ttg	ctg	gcg	aag	ttc	aag	ggc	cac	288
Val	Thr	Ala	His	Lys	Val	Thr	Pro	Leu	Leu	Ala	Lys	Phe	Lys	Gly	His	
				85				90					95			

cgg	atg	gcg	aag	ggc	gcg	ctg	gag	atg	gcg	gtc	ctc	gac	gcc	gaa	ctc	336
Arg	Met	Ala	Lys	Gly	Ala	Leu	Glu	Met	Ala	Val	Leu	Asp	Ala	Glu	Leu	
			100					105					110			

55

cgc	gcg	cat	gac	cgg	tcc	ttc	gcg	gcc	gag	ctg	ggg	tcc	act	cgc	gac	384
Arg	Ala	His	Asp	Arg	Ser	Phe	Ala	Ala	Glu	Leu	Gly	Ser	Thr	Arg	Asp	
		115					120					125				

tcc	gtg	gcc	tgc	ggg	gtc	tcg	gtc	ggg	atc	atg	gac	tcg	atc	ccg	cac	432
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

	Ser	Val	Ala	Cys	Gly	Val	Ser	Val	Gly	Ile	Met	Asp	Ser	Ile	Pro	His	
	130						135					140					
5	ctg	ctc	gac	gtc	gtc	ggc	ggc	tac	ctc	gac	gag	ggc	tac	gtc	cgg	atc	480
	Leu	Leu	Asp	Val	Val	Gly	Gly	Tyr	Leu	Asp	Glu	Gly	Tyr	Val	Arg	Ile	
	145					150					155					160	
10	aag	ctg	aag	atc	gag	ccc	ggc	tgg	gac	gtc	gag	ccg	gtc	cgg	cag	gtg	528
	Lys	Leu	Lys	Ile	Glu	Pro	Gly	Trp	Asp	Val	Glu	Pro	Val	Arg	Gln	Val	
					165					170					175		
15	cgt	gag	cgc	ttc	ggc	gac	gac	gtg	ctg	ctg	cag	gtc	gac	gcg	aac	acc	576
	Arg	Glu	Arg	Phe	Gly	Asp	Asp	Val	Leu	Leu	Gln	Val	Asp	Ala	Asn	Thr	
				180					185					190			
	gcg	tac	acg	ctg	ggc	gac	gcg	ccc	ctg	ctg	tcc	cgg	ctc	gac	ccg	ttc	624
	Ala	Tyr	Thr	Leu	Gly	Asp	Ala	Pro	Leu	Leu	Ser	Arg	Leu	Asp	Pro	Phe	
			195					200					205				
20	gac	ctg	ctg	ctg	atc	gag	cag	ccg	ctc	gaa	gaa	gag	gac	gtg	ctc	ggc	672
	Asp	Leu	Leu	Leu	Ile	Glu	Gln	Pro	Leu	Glu	Glu	Glu	Asp	Val	Leu	Gly	
		210					215					220					
25	cac	gcc	gag	ctg	gcc	aag	cgg	atc	cgg	acg	ccg	atc	tgc	ctc	gac	gag	720
	His	Ala	Glu	Leu	Ala	Lys	Arg	Ile	Arg	Thr	Pro	Ile	Cys	Leu	Asp	Glu	
	225					230					235					240	
30	tcg	atc	gtc	tcg	gcc	aag	gcc	gcc	gcg	gac	gcg	atc	aag	ctc	ggc	gcc	768
	Ser	Ile	Val	Ser	Ala	Lys	Ala	Ala	Ala	Asp	Ala	Ile	Lys	Leu	Gly	Ala	
					245					250					255		
35	tgc	cag	atc	gtc	aac	atc	aaa	ccg	ggc	cgg	gtc	ggc	gga	tac	ctc	gaa	816
	Cys	Gln	Ile	Val	Asn	Ile	Lys	Pro	Gly	Arg	Val	Gly	Gly	Tyr	Leu	Glu	
				260					265					270			
	gcc	cgc	cgg	gtg	cac	gac	gtc	tgc	gcg	gca	cac	ggg	atc	gcg	gtg	tgg	864
	Ala	Arg	Arg	Val	His	Asp	Val	Cys	Ala	Ala	His	Gly	Ile	Ala	Val	Trp	
			275					280					285				
40	tgc	ggc	ggg	atg	atc	gag	acc	ggg	ctc	ggc	cgg	gcg	gcc	aac	gtc	gca	912
	Cys	Gly	Gly	Met	Ile	Glu	Thr	Gly	Leu	Gly	Arg	Ala	Ala	Asn	Val	Ala	
		290					295					300					
45	ctg	gcc	tcg	ctg	ccc	ggc	ttc	acg	ctg	ccg	ggg	gac	acc	tcg	gcg	tcc	960
	Leu	Ala	Ser	Leu	Pro	Gly	Phe	Thr	Leu	Pro	Gly	Asp	Thr	Ser	Ala	Ser	
	305					310					315					320	
50	ggc	cgg	ttc	tat	cgc	acc	gac	atc	acc	gag	ccg	ttc	gtg	ctg	gac	gcc	1008
	Gly	Arg	Phe	Tyr	Arg	Thr	Asp	Ile	Thr	Glu	Pro	Phe	Val	Leu	Asp	Ala	
					325					330					335		
55	ggg	cat	ctg	ccg	gtg	ccg	acc	ggg	ccg	ggc	ctc	ggg	gtg	act	ccg	att	1056
	Gly	His	Leu	Pro	Val	Pro	Thr	Gly	Pro	Gly	Leu	Gly	Val	Thr	Pro	Ile	
				340					345					350			
	ccg	gat	ctt	ctg	gac	gag	gtc	acc	acg	gag	aaa	gcg	tgg	atc	ggc	tcg	1104
	Pro	Asp	Leu	Leu	Asp	Glu	Val	Thr	Thr	Glu	Lys	Ala	Trp	Ile	Gly	Ser	
			355					360					365				

tag

1107

```

5  <210> 2
   <211> 368
   <212> PRT
   <213> Amycolatopsis orientalis

10 <400> 2
   Val Lys Leu Ser Gly Val Glu Leu Arg Arg Val Arg Met Pro Leu Val
     1      5      10      15
   Ala Pro Phe Arg Thr Ser Phe Gly Thr Gln Ser Glu Arg Glu Leu Leu
     20      25      30
15  Leu Val Arg Ala Val Thr Pro Ala Gly Glu Gly Trp Gly Glu Cys Val
     35      40      45
   Ala Met Glu Ala Pro Leu Tyr Ser Ser Glu Tyr Asn Asp Ala Ala Glu
     50      55      60
   His Val Leu Arg Asn His Leu Ile Pro Ala Leu Leu Ala Ala Glu Asp
     65      70      75      80
20  Val Thr Ala His Lys Val Thr Pro Leu Leu Ala Lys Phe Lys Gly His
     85      90      95
   Arg Met Ala Lys Gly Ala Leu Glu Met Ala Val Leu Asp Ala Glu Leu
     100     105     110
25  Arg Ala His Asp Arg Ser Phe Ala Ala Glu Leu Gly Ser Thr Arg Asp
     115     120     125
   Ser Val Ala Cys Gly Val Ser Val Gly Ile Met Asp Ser Ile Pro His
     130     135     140
   Leu Leu Asp Val Val Gly Gly Tyr Leu Asp Glu Gly Tyr Val Arg Ile
     145     150     155     160
30  Lys Leu Lys Ile Glu Pro Gly Trp Asp Val Glu Pro Val Arg Gln Val
     165     170     175
   Arg Glu Arg Phe Gly Asp Asp Val Leu Leu Gln Val Asp Ala Asn Thr
     180     185     190
35  Ala Tyr Thr Leu Gly Asp Ala Pro Leu Leu Ser Arg Leu Asp Pro Phe
     195     200     205
   Asp Leu Leu Leu Ile Glu Gln Pro Leu Glu Glu Glu Asp Val Leu Gly
     210     215     220
   His Ala Glu Leu Ala Lys Arg Ile Arg Thr Pro Ile Cys Leu Asp Glu
     225     230     235     240
40  Ser Ile Val Ser Ala Lys Ala Ala Ala Asp Ala Ile Lys Leu Gly Ala
     245     250     255
   Cys Gln Ile Val Asn Ile Lys Pro Gly Arg Val Gly Gly Tyr Leu Glu
     260     265     270
45  Ala Arg Arg Val His Asp Val Cys Ala Ala His Gly Ile Ala Val Trp
     275     280     285
   Cys Gly Gly Met Ile Glu Thr Gly Leu Gly Arg Ala Ala Asn Val Ala
     290     295     300
   Leu Ala Ser Leu Pro Gly Phe Thr Leu Pro Gly Asp Thr Ser Ala Ser
     305     310     315     320
50  Gly Arg Phe Tyr Arg Thr Asp Ile Thr Glu Pro Phe Val Leu Asp Ala
     325     330     335
   Gly His Leu Pro Val Pro Thr Gly Pro Gly Leu Gly Val Thr Pro Ile
     340     345     350
55  Pro Asp Leu Leu Asp Glu Val Thr Thr Glu Lys Ala Trp Ile Gly Ser
     355     360     365

```

### Examples:

Detection of racemase activity of the recombinant AAR enzyme

The substrate spectrum of the N-acetylamino acid racemase  
5 from *Amycolatopsis orientalis* subsp. *lurida* was tested  
using the enzyme assay described below.

The assay was composed of the following:

Tris/HCl buffer	50 mM (pH 8.0)
10 Substrate	25 mM
Cobalt chloride	6 mM
AAR	approx 150 µg purified protein
Final volume	1 ml

Enantiomerically pure amino acid derivatives were used in  
15 the test and the formation of the corresponding racemate  
was monitored in the polarimeter (Perkin-Elmer 241).  
Incubation took place at 30°C (heated cell) for 3 to 12  
hours. The measurements were taken at a wavelength  $\lambda$  =  
365 nm.

Table 1: List of the substrates tested and of the corresponding specific activity of the AAR.

Substrate	Specific activity
<i>N</i> -Carbamoyl-D-Met	155 mU/mg
<i>N</i> -Carbamoyl-D-Phe	20 mU/mg
<i>N</i> -Carbamoyl-L-Abs	15 mU/mg
<i>N</i> -Carbamoyl-L-Leu	20 mU/mg
<i>N</i> -Carbamoyl-L-Met	118 mU/mg
<i>N</i> -Carbamoyl-L-Tyr	62 mU/mg
<i>N</i> -Carbamoyl-L-Val	20 mU/mg

5

The *N*-acyl amino acid racemase from *A. TS-1-60* with *N*-carbamoyl-D-Met as substrate has an activity of 100 mU/mg. This specific activity is thus 35% lower than that of the racemase from *A. orientalis* subsp. *lurida*.

10


## Patent claims:

1. Use of N-acetylamino acid racemases (AAR) from  
Amycolatopsis orientalis subspecies lurida in a  
process for the racemisation of N-carbamoylamino  
5 acids.
2. The use as claimed in claim 1 in a process for the  
preparation of enantiomerically enriched amino acids  
or derivatives thereof starting from hydantoins or N-  
carbamoylamino acids.
- 10 3. The use as claimed in one of the preceding claims,  
wherein  
the process is carried out in an enzyme-membrane  
reactor.

## Abstract:

The invention relates to the use of the N-acetylamino acid racemase from *Amycolatopsis orientalis* subspecies *lurida* for the racemisation of N-carbamoylamino acids.

- 5 This use permits the 100% preparation of optically pure amino acids starting from racemic hydantoins in an enzymatic overall process.



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for [ ] Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Appl Microbiol Biotechnol. 2001 Apr;55(3):354-61.

Related Articles, Links

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

Privacy Policy

## Screening, overexpression and characterization of an N-acetylaminic acid racemase from *Amycolatopsis orientalis* subsp. *lurida*.

Verseck S, Bommarius A, Kula MR.

Institute of Enzyme Technology of the Heinrich-Heine-University Duesseldorf, Julich, Germany.

Thirty-one different actinomycete strains were used in a genetic screening using PCR and Southern hybridization methods to detect N-acetylaminic acid racemases (AAR) in order to obtain enzymes with different properties. Cloning and sequencing of a 2.5 kb EcoRI DNA fragment from *Amycolatopsis orientalis* subsp. *lurida* revealed the coding gene of an N-acetylaminic acid racemase, which had identities to the *aar* gene of *Amycolatopsis* sp. TS-1-60 [Tokuyama and Hatano (1995) Appl Microbiol Biotechnol 42:884-889] of 86% at the level of DNA, and 90% at the level of amino acids. The heterologous overexpression in *Escherichia coli* resulted in a specific activity of about 0.2 U/mg of this racemase. A two-step purification with heat treatment followed by anion-exchange chromatography led to almost homogeneous enzyme. The optimum pH of the enzyme was 8.0 and it was stable at 50 degrees C for 30 min. The relative molecular mass of the native enzyme and the subunit was calculated to be 300 kDa and 40 kDa by gel filtration and SDS-PAGE, respectively. The isoelectric point (pI) of the AAR was 4.4. It catalyzed the racemization of optically active N-acetylaminic acids such as N-acetyl-L- or -D-methionine and N-acetyl-L-phenylalanine. Further characterization of the racemase demonstrated a requirement for divalent metal ions (Co<sup>2+</sup>, Mn<sup>2+</sup>, Mg<sup>2+</sup>) for activity and inhibition by EDTA and p-hydroxymercuribenzoic acid. AAR is sensitive to substrate inhibition at concentrations exceeding 200 mM.

PMID: 11341319 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk  
NCBI | NLM | NIH  
Department of Health & Human Services  
Freedom of Information Act | Disclaimer

Jan 29 2004 15:06:34